Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances

Journal of Neuroscience

Volumn 29, Issue 47, 2009, Pages 14764-14769

  Ren, Yanhua ^a   Whittard, John ^a   Higuera Matas, Alejandro ^b   Morris, Claudia V ^a   Hurd, Yasmin L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABIS; COMPLEMENTARY DNA; DIAMORPHINE; GLUTAMATE RECEPTOR 1; RNA;

ADDICTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INFUSION; DRUG SELF ADMINISTRATION; EXPERIMENTAL MODEL; HEROIN DEPENDENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJECTION; LIMBIC SYSTEM; MALE; MENTAL DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RELAPSE; WITHDRAWAL SYNDROME;

ANIMALS; CANNABIDIOL; CONDITIONING (PSYCHOLOGY); CUES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GLUTAMIC ACID; HEROIN; HEROIN DEPENDENCE; LIMBIC SYSTEM; MALE; NARCOTIC ANTAGONISTS; NARCOTICS; NEURAL PATHWAYS; NUCLEUS ACCUMBENS; RATS; RATS, LONG-EVANS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, AMPA; TREATMENT OUTCOME; VENTRAL TEGMENTAL AREA;

EID: 72449197981     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4291-09.2009     Document Type: Article

References (35)

1. Anderson SM, Famous KR, Sadri-Vakili G, Kumaresan V, Schmidt HD, Bass CE, Terwilliger EF, Cha JH, Pierce RC (2008) CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nat Neurosci 11:344-353. (Pubitemid 351311801)
2. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486.
3. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212-1213. (Pubitemid 35398785)
4. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852. (Pubitemid 33016156)
5. Childress AR, Hole AV, Ehrman RN, Robbins SJ, McLellan AT, O'Brien CP (1993) Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr 137:73-95.
6. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y, Marinelli M, Wolf ME (2008) Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 454:118-121. (Pubitemid 351931970)
7. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40:701-708.
8. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417-426. (Pubitemid 38175159)
9. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168:164-169. (Pubitemid 36851175)
10. Ellgren M, Spano SM, Hurd YL (2007) Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32:607-615. (Pubitemid 46271055)
11. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
12. Guimarães FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161-164. (Pubitemid 24055428)
13. Hall W, Degenhardt L (2008) Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 7:68-71.
14. Hurd YL (2003) In situ hybridization with isotopic riboprobes for detection of striatal neuropeptide mRNA expression after dopamine stimulant administration. Methods Mol Med 79:119-135.
15. Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162:1403-1413.
16. Katona I, Freund TF (2008) Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14:923-930.
17. Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8:844-858.
18. LaLumiere RT, Kalivas PW (2008) Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 28:3170-3177.
19. Mechoulam R (1970) Marihuana chemistry. Science 168:1159-1166.
20. Moreira FA, Aguiar DC, Guimarães FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466-1471.
21. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004) Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175:360-366. (Pubitemid 39361924)
22. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, Ed 5. Amsterdam: Elsevier.
23. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231-6238.
24. Rodriguez JJ, Mackie K, PickelVM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823-833.
25. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ (2006) Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781. (Pubitemid 44308340)
26. See RE (2002) Neural substrates of conditioned-cued relapse to drug-seeking behavior. Pharmacol Biochem Behav 71:517-529.
27. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168:3-20. (Pubitemid 36851158)
28. Sinha R, Fuse T, Aubin LR, O'Malley SS (2000) Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) 152:140-148. (Pubitemid 30776406)
29. Solinas M, Panlilio LV, Goldberg SR (2004) Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 29:1301-1311. (Pubitemid 38780653)
30. Spano MS, Ellgren M, Wang X, Hurd YL (2007) Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry 61:554-563. (Pubitemid 46185333)
31. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613-623. (Pubitemid 46355558)
32. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15:349-353. (Pubitemid 44434985)
33. Van den Oever MC, Goriounova NA, Li KW, Van der Schors RC, Binnekade R, Schoffelmeer AN, Mansvelder HD, Smit AB, Spijker S, De Vries TJ (2008) Prefrontal cortex AMPA receptor plasticity is crucial for cue-induced relapse to heroin-seeking. Nat Neurosci 11:1053-1058.
34. Walter M, Wiesbeck GA, Bloch N, Aeschbach S, Olbrich HM, Seifritz E, Dürsteler-MacFarland KM (2008) Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol 18:390-393.
35. Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA (2006) Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20:683-686.